Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma
Sai Sanikommu, Alejandro N. Santos, Bashar Dawoud, Khushi H. Shah, Sima Vazquez, Ashish H. Shah, Victor M. Lu · 2026
Read Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma by Sai Sanikommu, Alejandro N. Santos, Bashar Dawoud, Khushi H. Shah, Sima Vazquez, Ashish H. Shah, Victor M. Lu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427997.txt.
Description
Sai Sanikommu and colleagues review, in a 2026 paper, early trials of engineered immune cells against brain tumors in children and young adults. CAR-T therapy retrains a patient's own T cells to hunt a chosen target, and it works well in blood cancers. Solid brain tumors are a harder test. The review gathered eight early phase trials covering 74 patients, of whom 63 received cell infusions.
Targets included markers named B7-H3, GD2, and HER2, given into the fluid spaces of the brain, into a vein, or both. All patients had heavy prior treatment, and many tumors had returned. No deaths were caused by the therapy itself. Immune side effects were common yet reversible with steroids and related drugs. About two thirds of judged patients at least held their disease stable, while clear shrinkage stayed rare.
Catalog record
| CREATOR | Sai Sanikommu, Alejandro N. Santos, Bashar Dawoud, Khushi H. Shah, Sima Vazquez, Ashish H. Shah, Victor M. Lu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62263 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |